Personalis Q2 FY26 net loss widens to $31.68 million; revenue rises 30% to $22.36 million

Reuters2026/08/04 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Personalis posted Q2 revenue growth of 30% to USD 22.4 million, while net loss widened to USD 31.68 million, or USD 0.30 a share.
Clinical diagnostic revenue more than doubled to USD 2.6 million, while clinical test volume rose 199% year over year to 10,384 tests.
Pharma testing services revenue climbed 51% to USD 16.79 million, while population sequencing revenue slipped 9% to USD 3 million.
Medicare coverage expanded NeXT Personal reimbursement to four indications, adding approvals for immunotherapy monitoring and neoadjuvant breast cancer monitoring.
Chris Hall said more than 1,400 physicians ordered NeXT Personal; Personalis withdrew guidance following its Tempus merger agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Personalis Q2 FY26 net loss widens to $31.68 million; revenue rises 30% to $22.36 million

You may also like

Crypto prices